Homepage
Medication Guide
Indications for Cemiplimab
Cemiplimab is an important immunotherapeutic agent classified as a programmed death receptor-1 (PD-1) blocking antibody. As a significant breakthrough in the field of cancer immunotherapy in recent ye...
506
Monday, October 13th, 2025, 14:39
Precautions for Anagrelide (Agrylin) Administration
Anagrelide (Agrylin) is a thrombocytopenic agent primarily used to treat thrombocythemia secondary to myeloproliferative neoplasms. It reduces platelet counts, lowers the risk of thrombosis, and impro...
510
Monday, October 13th, 2025, 14:36
How to Use Anagrelide (Agrylin)
Anagrelide (Agrylin) is a selective thrombocytopenic agent primarily used to treat thrombocythemia secondary to myeloproliferative neoplasms. It reduces the risk of thrombosis and improves related sym...
507
Monday, October 13th, 2025, 14:33
What Are the Side Effects of Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted MET kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. As a...
505
Monday, October 13th, 2025, 14:30
How Effective is Capmatinib (Tabrecta) in Treatment?
Capmatinib (Tabrecta) is a targeted therapeutic agent that has demonstrated favorable efficacy in the treatment of specific types of non-small cell lung cancer (NSCLC) in recent years. As a kinase inh...
508
Monday, October 13th, 2025, 14:14
Precautions for Capmatinib (Tabrecta) Administration
Capmatinib (Tabrecta) is a kinase inhibitor targeting metastatic non-small cell lung cancer (NSCLC) with METex14 skipping mutation. Its efficacy has been verified in clinical trials; however, during m...
507
Monday, October 13th, 2025, 14:10
Precautions for Capmatinib (Tabrecta) Administration
Capmatinib (Tabrecta) is a kinase inhibitor targeting metastatic non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutations. Its efficacy has been validated in clinical trials; h...
509
Saturday, October 11th, 2025, 17:16
Indication of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a small-molecule inhibitor targeting the MET kinase, developed by Novartis and granted accelerated approval by the U.S. FDA in 2020. As a precision therapy, it has demonstrate...
510
Saturday, October 11th, 2025, 17:13
How to Administer Cemiplimab
Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not ca...
511
Saturday, October 11th, 2025, 16:25
Precautions for Cemiplimab Administration
Cemiplimab is a PD-1 inhibitor indicated for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radia...
504
Saturday, October 11th, 2025, 16:03
94 / 208
2071 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved